UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET Company Participants George Elston - Chief Financial Officer & Head, Corporate Development Nancy Lurker - President & Chief Executive Officer Jay Duker - Chief Strategic Scientific Officer Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Georgi Yordanov - Cowen and Company Yatin Suneja - Guggenheim Partners Yi Chen - H.C. Wainwright Yale Jen - Laidlaw An ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2021 Earnings Conference Call May 5, 2021 8:30 AM ET Company Participants George Elston - CFO & Head, Corporate Development Nancy Lurker - President, CEO & Director Jay Duker - Chief Strategic Scientific Officer Scott Jones - Chief Commercial Officer Conference Call Participants Georgi Yordanov - Cowen and Company Jennifer Kim - Cantor Fitzgerald & Co. Devin Geiman - Guggenheim Securities Yi Chen - H.C. Wainwright & Co. Andrew D'Silva - B. Riley Securities I-E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorp ...

Delivering Innovation to the Eye Investor Presentation March 2021 1 | EYEPOINT PHARMACEUTICALS Forward Looking Statements Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or other jurisdiction of in ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2020 Earnings Conference Call March 4, 2021 8:30 AM ET Company Participants George Elston – Chief Financial Officer Nancy Lurker – President and Chief Executive Officer Jay Duker – Chief Strategic Scientific Officer Scott Jones – Chief Commercial Officer Dario Paggiarino – Senior Vice President and Chief Medical Officer Conference Call Participants Jennifer Kim – Cantor Fitzgerald Dana Flanders – Guggenheim Yale Jen – Laidlaw and Company Andrew D'Silva – B. Ri ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2020 Results Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - President and CEO Jay Duker - Chief Strategic Scientific Officer Scott Jones - Chief Commercial Officer Dario Paggiarino - Senior Vice President and CMO Conference Call Participants Andrew D'Silva - B. Riley Operator Good morning. My name is Bridget, and I’ll be your conference operator today. At this time, I would like ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2020 Results Earnings Conference Call August 5, 2020 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - President and CEO Dr. Jay Duker - Chief Strategic Scientific Officer Scott Jones - Chief Commercial Officer Dr. Dario Paggiarino - Senior Vice President and CMO Conference Call Participants I-Eh Jen - Laidlaw & Co. Yi Chen - H.C. Wainwright Andrew D’Silva - B. Riley FBR Dana Flanders - Guggenheim Operator Good morning. My ...